PROPOSED NEW MERGER WITH ANI (Details) (USD $)	0 Months Ended
	Apr. 12, 2013
New Merger Agreement
PROPOSED NEW MERGER WITH ANI
Percentage of outstanding shares of common stock owned by stockholders of the Company immediately prior to the effective time of merger	43.00%
New Merger Agreement | Subsequent Event
PROPOSED NEW MERGER WITH ANI
Percentage of outstanding shares of common stock owned by stockholders of the Company immediately prior to the effective time of merger	43.00%
Number of current directors of the company in board of directors of the company immediately following the effective time of the merger	2
New Merger Agreement | Subsequent Event | Maximum
PROPOSED NEW MERGER WITH ANI
Termination fee payable under specified circumstances	1,000,000
Reimbursement of expenses in connection with merger	500,000
ANI Pharmaceuticals, Inc | New Merger Agreement
PROPOSED NEW MERGER WITH ANI
Percentage of outstanding shares of common stock owned by stockholders of ANI immediately prior to the effective time of merger	57.00%
ANI Pharmaceuticals, Inc | New Merger Agreement | Subsequent Event
PROPOSED NEW MERGER WITH ANI
Number of fractional shares of common stock to be issued in connection with the merger	0
Percentage of outstanding shares of common stock owned by stockholders of ANI immediately prior to the effective time of merger	57.00%
Number of current directors of the subsidiary in board of directors of the company immediately following the effective time of the merger	5
ANI Pharmaceuticals, Inc | New Merger Agreement | Subsequent Event | Maximum
PROPOSED NEW MERGER WITH ANI
Termination fee payable under specified circumstances	750,000
ANI Pharmaceuticals, Inc | Voting Agreements | Subsequent Event
PROPOSED NEW MERGER WITH ANI
Percentage of outstanding shares of capital stock held by stockholders as of the close of business	90.00%
Number of stockholders holding 57 percent of outstanding shares of common stock	1
Percentage of outstanding shares of common stock held by stockholders who agreed to vote in favor of election of directors	57.00%
Number of directors designated by the entity at the first annual meeting of stockholders following the completion of the New Merger	2
Percentage of outstanding shares of common stock held collectively by specified personnel who entered into voting agreements	2.00%
ANI Pharmaceuticals, Inc | Lock-Up Agreements | Subsequent Event
PROPOSED NEW MERGER WITH ANI
Percentage of outstanding shares of common stock held collectively by specified personnel who entered into voting agreements	85.00%
Locking period on the sale of shares of the Company's common stock received in the New Merger	6 months
ANI Pharmaceuticals, Inc | Lock-Up Agreements | Subsequent Event | Maximum
PROPOSED NEW MERGER WITH ANI
Portion of shares held by chief executive officer and chief financial officer of the subsidiary that is permitted to be sold (as a percent)	50.00%
ANI Pharmaceuticals, Inc | Contingent Value Rights Agreement | Subsequent Event
PROPOSED NEW MERGER WITH ANI
Number of contingent value rights issued in exchange for one share of common stock (in shares)	1
Period during which net cash payments can be received after distribution of rights	10 years
Net cash payments to be distributed to holders of the CVRs expressed as percentage of net cash payments received	66.00%
Net cash payments to be distributed to holders of the CVRs expressed as percentage of net revenues from direct sales of LibiGel products after New Merger	5.00%
ANI Pharmaceuticals, Inc | Contingent Value Rights Agreement | Subsequent Event | Maximum
PROPOSED NEW MERGER WITH ANI
Additional development expenses assumed to be incurred for net cash payments to be distributed to holders of the CVRs	2,500,000
Aggregate net cash payments to be distributed to holders of CVRs	50,000,000